Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Merrill Cuts King Pharmaceuticals to 'Neutral'

Merrill Lynch downgraded King Pharmaceuticals (KG) to neutral from buy.

Analyst Gregory Gilbert says the Securities and Exchange Commission subpoenaed documents related to sales of certain products in 1999 and 2000, as well as certain pricing issues and other general requests. Gilbert says the investigation is a surprise to him, and believes it is a surprise to investors as well. He says management was not aware of any inappropriate action taken by the company.

Gilbert notes the underlying reason for the probe is not disclosed. He also says it is now difficult to recommend the purchase of King shares until there's more clarity on the situation. He sees $1.70 2003 earnings per share (GAAP), and $2.14 for 2004.

blog comments powered by Disqus